Compare IQV & DEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | DEO |
|---|---|---|
| Founded | 1982 | 1886 |
| Country | United States | United Kingdom |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 48.2B |
| IPO Year | 2013 | 2001 |
| Metric | IQV | DEO |
|---|---|---|
| Price | $270.87 | $87.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | ★ $227.13 | $109.00 |
| AVG Volume (30 Days) | ★ 1.3M | 848.4K |
| Earning Date | 05-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 4.18% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $9,739,000,000.00 | N/A |
| Revenue This Year | $6.77 | $2.65 |
| Revenue Next Year | $5.89 | N/A |
| P/E Ratio | $170.82 | ★ $90.04 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $72.45 |
| 52 Week High | $277.40 | $102.17 |
| Indicator | IQV | DEO |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 47.02 |
| Support Level | $159.91 | $87.09 |
| Resistance Level | $271.80 | $90.33 |
| Average True Range (ATR) | 6.37 | 1.21 |
| MACD | -0.65 | -0.07 |
| Stochastic Oscillator | 73.64 | 56.16 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.